(Q46017829)

English

High-dose VP-16 with intermediate-dose cytosine arabinoside in the treatment of relapsed acute nonlymphocytic leukemia.

scientific article published in January 1987

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/3677301

High-dose VP-16 with intermediate-dose cytosine arabinoside in the treatment of relapsed acute nonlymphocytic leukemia. (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/3677301

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

H Y Chan

1

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/3677301

F J Meyers

2

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/3677301

J P Lewis

3

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/3677301

publication date

1 January 1987

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/3677301

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/3677301

20

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/3677301

3

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/3677301

265-266

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/3677301

https://scigraph.springernature.com/pub.10.1007/bf00570500

0 references

Treatment failure in AML.

1 reference

https://pubmed.ncbi.nlm.nih.gov/3677301

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The use of intermediate dose cytosine arabinoside (ID Ara-C) in the treatment of acute non-lymphocytic leukaemia in relapse

1 reference

https://pubmed.ncbi.nlm.nih.gov/3677301

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical trials of adult acute nonlymphocytic leukemia: evidence of progress

1 reference

https://pubmed.ncbi.nlm.nih.gov/3677301

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose etoposide for refractory malignancies: a phase I study

1 reference

https://pubmed.ncbi.nlm.nih.gov/3677301

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/3677301

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/BF00570500

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/3677301

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/3677301

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46017829&oldid=1582963768"